Gilead Sciences ((GILD)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gilead Sciences, in collaboration with Arcus Biosciences, is conducting a Phase 2 clinical study titled ‘VELOCITY-Lung’ to evaluate the safety and efficacy of novel treatment combinations in patients with lung cancer. This study aims to assess the objective response rate and complete pathological response rate in different substudies involving patients with metastatic and resectable non-small-cell lung cancer (NSCLC).
The study tests several experimental drug combinations, including Zimberelimab, Domvanalimab, Sacituzumab govitecan-hziy, and Etrumadenant, against standard care treatments. These drugs are administered either intravenously or orally, depending on the combination.
This interventional study is randomized with a parallel assignment model and is open-label, meaning no masking is involved. Its primary purpose is treatment-focused, aiming to improve outcomes for lung cancer patients.
The study began on November 21, 2022, with an estimated primary completion date not yet specified. The latest update was submitted on September 1, 2025, indicating ongoing recruitment and progress.
The outcome of this study could significantly impact Gilead Sciences’ stock performance and investor sentiment, especially if the novel treatments show promising results. It could also influence the competitive landscape in the lung cancer treatment market, where innovation is crucial.
The study is ongoing, and further details are available on the ClinicalTrials portal.